Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
THEOPHYL vs AEROLONE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Theophylline is a methylxanthine that causes bronchodilation primarily through inhibition of phosphodiesterase (PDE) and antagonism of adenosine receptors. It also has mild anti-inflammatory effects and enhances mucociliary clearance.
Selective beta2-adrenergic receptor agonist that relaxes bronchial smooth muscle by increasing cyclic AMP production via adenylate cyclase activation.
Treatment of symptoms and prevention of asthma,Treatment of chronic obstructive pulmonary disease (COPD),Apnea of prematurity (off-label)
Treatment of bronchospasm in patients with COPD,Long-term maintenance treatment of asthma
300 mg orally every 6 hours or 400-600 mg extended-release orally every 12-24 hours; intravenous loading dose 5-6 mg/kg over 20-30 minutes, then continuous infusion 0.4-0.6 mg/kg/h
AEROLONE is not a recognized drug; no standard dosing available.
Terminal elimination half-life: Adults nonsmokers: 6–12 h (mean 8.7 h); adult smokers: 4–5 h; children: 3–5 h; neonates: 20–30 h; hepatic cirrhosis: up to 30 h. Half-life increases with congestive heart failure, fever, and concurrent CYP1A2 inhibitors (e.g., cimetidine, fluvoxamine).
Terminal elimination half-life is approximately 12-15 hours in adults; prolonged to 24-30 hours in severe renal impairment (Cr Cl <30 m L/min).
Primarily metabolized by hepatic CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Metabolism is saturable, leading to non-linear pharmacokinetics.
Primarily metabolized by CYP3A4 and to a lesser extent CYP2D6, with conjugation to inactive metabolites.
Renal: 10% unchanged in adults (higher in neonates). Hepatic metabolism to inactive metabolites (1,3-dimethyluric acid, 3-methylxanthine, 1-methyluric acid) excreted renally; fecal excretion <5%.
Primarily renal excretion of unchanged drug (approximately 65%) and hepatic metabolism (35%), with metabolites excreted in urine and feces. Biliary/fecal elimination accounts for <10%.
40% bound, primarily to albumin.
Approximately 88% bound, primarily to albumin and alpha-1-acid glycoprotein.
0.3–0.7 L/kg (mean 0.45 L/kg). Higher Vd in neonates (0.6–0.9 L/kg) and patients with cirrhosis. Vd approximates total body water; distribution is rapid into well-perfused tissues, less into adipose tissue.
3.5-5.0 L/kg, indicating extensive extravascular distribution and tissue binding.
Oral immediate-release: 96%–100% (almost complete). Oral sustained-release: 80%–100% (variable due to formulation-dependent release; food may increase rate but not extent for some products). Rectal: variable, approximately 80–90% (solution/suppository dependent).
Oral: 35-50% (first-pass metabolism); Inhalation: 15-30% (dependent on device and technique); Intravenous: 100%.
No dose adjustment required for GFR > 10 m L/min; for GFR < 10 m L/min, reduce dose by 50% and monitor serum levels
No data; not applicable.
Child-Pugh A: reduce dose by 50%; Child-Pugh B: reduce dose by 75%; Child-Pugh C: avoid use or use with extreme caution and monitor levels
No data; not applicable.
Initial 5 mg/kg/day in divided doses every 6-8 hours, titrate based on serum levels; typical maintenance: 1-12 years: 20 mg/kg/day (max 800 mg/day), >12 years: 16 mg/kg/day (max 900 mg/day)
No data; not applicable.
Start at lower end of dosing range (e.g., 300 mg/day extended-release) with frequent monitoring due to decreased clearance; avoid doses exceeding 400 mg/day without serum level guidance
No data; not applicable.
No FDA black box warning for theophylline.
None
Narrow therapeutic index; monitor serum levels. Risk of cardiac arrhythmias and seizures, especially at high levels. Use with caution in patients with cardiac disease, hepatic impairment, or those receiving other methylxanthines.
Paradoxical bronchospasm,Cardiovascular effects (e.g., increased heart rate, QT prolongation),Hypokalemia,Hyperglycemia
Hypersensitivity to theophylline or any component of the formulation. Concurrent use of other methylxanthines.
Hypersensitivity to arformoterol or any component of the formulation
High-carbohydrate, low-protein diets can increase theophylline toxicity by reducing clearance. Charcoal-broiled meats and cruciferous vegetables (broccoli, Brussels sprouts, kale) may increase metabolism, potentially reducing efficacy. Avoid large amounts of caffeine-containing products (coffee, tea, cola, energy drinks) as they can exacerbate CNS and cardiac adverse effects.
No significant food interactions. Avoid grapefruit juice as it may affect metabolism of the corticosteroid component.
Theophylline is not considered a major human teratogen. First trimester: Limited data show no increased risk of major malformations above baseline. Second and third trimesters: No known teratogenic effects; however, neonatal withdrawal (irritability, jitteriness, apnea) may occur with third-trimester exposure. High maternal levels may be associated with fetal tachycardia and intrauterine growth restriction.
No evidence of teratogenicity in animal studies at doses up to 10 mg/kg/day (approximately 120 times the maximum recommended human daily inhaled dose). In humans, no controlled studies exist; however, data from postmarketing reports do not suggest an increased risk of structural anomalies. First trimester: limited data preclude definitive risk assessment, but no pattern of major birth defects has emerged. Second and third trimesters: no known fetal harm from inhaled doses; however, potential for fetal adrenal suppression with prolonged high-dose systemic exposure.
Theophylline is excreted into breast milk with a milk-to-plasma ratio of approximately 0.7. Infant exposure is estimated at 1-10% of maternal weight-adjusted dose. Caution is advised; monitor infant for irritability or jitteriness. The American Academy of Pediatrics considers it compatible with breastfeeding, but risk-benefit assessment should be individualized.
Unknown whether fluticasone propionate is excreted in human breast milk. Other corticosteroids are excreted in breast milk in low amounts, and inhaled doses result in negligible systemic levels, predicting unlikely significant infant exposure. M/P ratio not determined. Caution advised; weigh risk of maternal obstructive airway disease exacerbation against potential infant risks (adrenal suppression, growth retardation).
Theophylline clearance decreases in the third trimester, leading to prolonged half-life. Dose reduction of 20-30% may be required to avoid toxicity. Monitor serum levels frequently (at least every 2-4 weeks) and adjust dose to maintain therapeutic concentrations. Postpartum, clearance returns to prepregnancy levels within 2-4 weeks, requiring upward dose adjustment.
No specific dose adjustment required based on pharmacokinetic changes; pregnancy may cause decreased airway reactivity but no significant changes in fluticasone clearance. Maintain lowest effective dose to control asthma. No dose increase recommended solely due to pregnancy. Monitor asthma control and adjust dose as per standard guidelines.
Theophylline has a narrow therapeutic index (5-15 mcg/m L). Monitor serum levels closely, especially when interacting drugs (e.g., cimetidine, fluoroquinolones, macrolides) are added or removed. Use with caution in patients with hepatic impairment, heart failure, or COPD exacerbation as clearance decreases. Cigarette smoking induces metabolism, requiring dose adjustments. Slow IV infusion over 20-30 minutes to avoid hypotension and arrhythmias.
AEROLONE is a combination inhaler containing an inhaled corticosteroid (fluticasone propionate) and a long-acting beta2-agonist (salmeterol). Advise patients to rinse mouth with water after each use to reduce risk of oral candidiasis. Not for acute bronchospasm; use a rescue inhaler (short-acting beta agonist) as needed. Monitor for increased heart rate, palpitations, or tremor. Do not stop abruptly; taper dose under medical supervision if discontinuing.
Take exactly as prescribed; do not change dose or stop without consulting your doctor.,Avoid smoking or use of nicotine products as they alter theophylline levels.,Report nausea, vomiting, insomnia, palpitations, or seizures immediately.,Limit caffeine intake (coffee, tea, chocolate, cola) as it may increase side effects.,Store medication at room temperature away from moisture and heat.,Keep regular appointments for blood level monitoring.
Use AEROLONE exactly as prescribed; do not exceed recommended dose.,Rinse your mouth with water after each use (do not swallow) to prevent thrush.,This medication is not for sudden breathing problems; always keep your rescue inhaler (e.g., albuterol) with you.,Do not stop using this medicine without talking to your doctor, as stopping suddenly may worsen your breathing.,Seek immediate medical help if you experience worsening asthma, chest pain, or allergic reaction.
"Theophylline, a cytochrome P450 (CYP) 1A2 substrate and inhibitor, may reduce the metabolic clearance of lobeglitazone, which is primarily metabolized by CYP1A2. This can lead to increased plasma concentrations of lobeglitazone, potentially enhancing its therapeutic effects and risk of adverse events such as peripheral edema, weight gain, and hypoglycemia. Clinically, patients receiving both drugs should be monitored for signs of lobeglitazone toxicity, and dose adjustments may be necessary."
"Pirfenidone, an antifibrotic agent used for idiopathic pulmonary fibrosis, inhibits CYP1A2 isoenzyme activity, which is the primary metabolic pathway for theophylline. Concomitant administration can lead to a significant increase in theophylline serum concentrations, elevating the risk of theophylline toxicity, including nausea, vomiting, cardiac arrhythmias, and seizures. Clinical monitoring and dose adjustment of theophylline are necessary to avoid adverse effects."
"Dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, may decrease the metabolic clearance of theophylline, a xanthine derivative bronchodilator, through competitive inhibition of cytochrome P450 (CYP) 1A2 enzymes. This interaction can lead to elevated serum theophylline concentrations, increasing the risk of theophylline toxicity, which may manifest as nausea, vomiting, arrhythmias, or seizures. Clinical monitoring and dose adjustment of theophylline are warranted to prevent adverse outcomes."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about THEOPHYL vs AEROLONE, answered by our medical review team.
THEOPHYL is a Bronchodilator that works by Theophylline is a methylxanthine that causes bronchodilation primarily through inhibition of phosphodiesterase (PDE) and antagonism of adenosine receptors. It also has mild anti-inflammatory effects and enhances mucociliary clearance.. AEROLONE is a Bronchodilator that works by Selective beta2-adrenergic receptor agonist that relaxes bronchial smooth muscle by increasing cyclic AMP production via adenylate cyclase activation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between THEOPHYL and AEROLONE depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of THEOPHYL is: 300 mg orally every 6 hours or 400-600 mg extended-release orally every 12-24 hours; intravenous loading dose 5-6 mg/kg over 20-30 minutes, then continuous infusion 0.4-0.6 mg/kg/h. The standard adult dose of AEROLONE is: AEROLONE is not a recognized drug; no standard dosing available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between THEOPHYL and AEROLONE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. THEOPHYL is classified as Category C. Theophylline is not considered a major human teratogen. First trimester: Limited data show no increased risk of major malformations above baseline. Second and third trimesters: No . AEROLONE is classified as Category C. No evidence of teratogenicity in animal studies at doses up to 10 mg/kg/day (approximately 120 times the maximum recommended human daily inhaled dose). In humans, no controlled stu. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.